Related Experiment Video

Updated: Jun 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic

K G Parhofer1, K I Birkeland, R DeFronzo

  • 1Medizinische Klinik II, Grosshadern, Klinikum der Universitaet, Munich, Germany. Klaus.Parhofer@med.unimuenchen.de

International Journal of Clinical Practice
|November 26, 2009
PubMed

Insights

Irbesartan did not improve insulin resistance in hypertensive patients with metabolic syndrome compared to hydrochlorothiazide. However, irbesartan showed benefits in reducing inflammation and microalbuminuria.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Angiotensin receptor blockers (ARBs) may reduce type 2 diabetes mellitus incidence.
  • The effect of short-term ARB therapy on metabolic parameters is not well-defined.

Purpose of the Study:

  • To evaluate the effect of irbesartan versus hydrochlorothiazide (HCTZ) on metabolic parameters.
  • To assess insulin resistance, lipid profiles, and inflammatory markers in hypertensive patients with metabolic syndrome.

Main Methods:

  • A 16-week randomized, controlled, double-blind trial (i-RESPOND).
  • Participants received irbesartan or HCTZ, with dose titration.
  • A subsequent 12-week period involved cross-over treatment.

Main Results:

  • Neither irbesartan nor HCTZ affected insulin resistance or beta-cell function at 16 weeks.
  • Irbesartan significantly reduced high-sensitivity C-reactive protein (hs-CRP) and urinary albumin/creatinine ratio (ACR) compared to HCTZ.
  • Both treatments were well-tolerated with comparable adverse events.

Conclusions:

  • Irbesartan did not demonstrate superior effects on insulin resistance compared to HCTZ.
  • Irbesartan may offer benefits for inflammation and microalbuminuria in hypertensive patients with metabolic syndrome.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...